Bioconjugate companies develop technologies that chemically link biological molecules to drugs, imaging agents, polymers or other functional components. These approaches are used to improve targeting, stability, delivery and detection across therapeutics, diagnostics and life science research.
This category includes companies working on:
Browse 50 UK bioconjugate companies below.
Custom modified oligonucleotides for research and therapeutics
ATDBio is a University of Southampton spin-out specialising in custom DNA and RNA oligonucleotide synthesis for research, diagnostics and therapeutic development. Its Southampton-based operations supply standard and chemically modified oligos, including antisense sequences, siRNA, aptamers and labelled probes, using…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate platform acts as a brain shuttle, enabling RNAi therapeutics to cross the blood brain barrier and reach the central nervous system through systemic…
CDMO and CRO for complex biologics and bioconjugate development
Abzena is an integrated CDMO and CRO specialising in complex biologics and bioconjugates, with cGMP facilities across the United States and a research presence in Cambridge, UK. Its services span antibody discovery, cell line development, bioconjugation and GMP manufacturing across monoclonal antibodies, antibody-drug…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
Gene therapy and biologics CDMO with cGMP manufacturing in Liverpool
Pharmaron Biologics (UK) Ltd is a contract development and manufacturing organisation specialising in biologics and cell and gene therapy, operating from cGMP biomanufacturing facilities in Speke, Liverpool. The site offers end-to-end services spanning plasmid design, cell line development, viral vector process…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City Place in London, the UK operation employs approximately 1,300 people and focuses on commercialisation, medical affairs, regulatory…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…
Contract immunoassay development and bioconjugation services
Fleet Bioprocessing is a Hampshire-based contract development and manufacturing organisation specialising in immunoassay development and bioconjugation. Founded in 2000 by former scientists from Johnson & Johnson and Amersham International, the company provides contract R&D and manufacturing services to diagnostics,…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule scaffold into two loops, conferring high-affinity target binding with the tissue penetration of small molecules. Its lead programme, a…
Global CDMO for drug development, delivery and manufacture
Catalent Pharma Solutions is a contract development and manufacturing organisation providing drug development, formulation, and manufacturing services across small molecules, biologics, cell and gene therapies, and consumer health products. The company offers proprietary drug delivery platforms including its orally…
European hub for RNAi therapeutics developer
Alnylam UK is the European operational headquarters of Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics. Based in Maidenhead, the UK office serves as Alnylam's primary base for European commercial operations, medical affairs, and regulatory activities. Alnylam has six approved RNAi medicines on…
Contract chemistry and manufacturing solutions for pharmaceutical and biotech research
Chemveda Life Sciences is a contract research and development organisation providing chemistry solutions to the pharmaceutical, biotechnology and agrochemical industries. The company offers discovery and medicinal chemistry, custom synthesis, route scouting and process research and development, alongside large scale,…
Bispecific antibody-drug conjugates for hard-to-treat solid tumours
Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology. Its proprietary discovery platform enables modular assembly of complex antibody formats combining multispecificity, multivalency, and drug conjugation,…
End-to-end lateral flow immunoassay development and manufacturing
Global Access Diagnostics (GADx) is a contract developer and manufacturer of rapid lateral flow immunoassay tests for human, veterinary, and agricultural applications. Operating as a social enterprise, GADx provides end-to-end diagnostic development services from assay design and antibody development through to…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers. Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than…
Bispecific antibody-drug conjugates for cancer-selective precision therapy
BiVictriX Therapeutics is a biopharmaceutical company developing bispecific antibody-drug conjugates for targeted cancer treatment. Its Bi-Cygni platform recognises combinations of two tumour-associated antigens to improve cancer-cell selectivity and limit effects on healthy tissues. Its lead solid-tumour candidate,…